{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:02:49Z","timestamp":1760821369574,"version":"3.41.2"},"reference-count":39,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T00:00:00Z","timestamp":1676505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1128\/ASMCopyrightv2"},{"start":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T00:00:00Z","timestamp":1676505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"UNITAID","award":["#2017-20-IMPAACT4TB"],"award-info":[{"award-number":["#2017-20-IMPAACT4TB"]}]},{"DOI":"10.13039\/100000061","name":"HHS | NIH | Fogarty International Center","doi-asserted-by":"publisher","award":["D43 TW009337"],"award-info":[{"award-number":["D43 TW009337"]}],"id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"HHS | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["K24AI150349"],"award-info":[{"award-number":["K24AI150349"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2023,2,16]]},"abstract":"<jats:p>Isoniazid pharmacokinetics are not yet well-described during once weekly, high-dose administrations with rifapentine (3HP) for latent tuberculosis infection (LTBI). Fewer data describe 3HP with dolutegravir-based antiretroviral therapy for the treatment of human immunodeficiency virus (HIV).<\/jats:p>","DOI":"10.1128\/aac.01297-22","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T14:44:28Z","timestamp":1673275468000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":3,"title":["High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus"],"prefix":"10.1128","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5822-351X","authenticated-orcid":true,"given":"Ryan T.","family":"Jarrett","sequence":"first","affiliation":[{"name":"Institute for Global Health, Vanderbilt University School of Medicine, Nashville, Tennessee, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuri","family":"van der Heijden","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA"},{"name":"Vanderbilt Tuberculosis Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA"},{"name":"The Aurum Institute, Johannesburg, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew S.","family":"Shotwell","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Violet","family":"Chihota","sequence":"additional","affiliation":[{"name":"Institute for Global Health, Vanderbilt University School of Medicine, Nashville, Tennessee, USA"},{"name":"Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA"},{"name":"The Aurum Institute, Johannesburg, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1670-8786","authenticated-orcid":true,"given":"Mark A.","family":"Marzinke","sequence":"additional","affiliation":[{"name":"Departments of Pathology and Medicine (Clinical Pharmacology), Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard E.","family":"Chaisson","sequence":"additional","affiliation":[{"name":"Department of Medicine Infectious Diseases, Johns Hopkins University Center for Tuberculosis Research, Baltimore, Maryland, USA"},{"name":"Department of International Health and Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9013-5256","authenticated-orcid":true,"given":"Kelly E.","family":"Dooley","sequence":"additional","affiliation":[{"name":"Departments of Pathology and Medicine (Clinical Pharmacology), Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"},{"name":"Department of Medicine Infectious Diseases, Johns Hopkins University Center for Tuberculosis Research, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gavin J.","family":"Churchyard","sequence":"additional","affiliation":[{"name":"Institute for Global Health, Vanderbilt University School of Medicine, Nashville, Tennessee, USA"},{"name":"The Aurum Institute, Johannesburg, South Africa"},{"name":"School of Public Health, University of Witwatersrand, Johannesburg, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002152"},{"key":"e_1_3_2_3_2","unstructured":"World Health Organization. 2018. Latent tuberculosis infection: updated and conosolidated guidelines for programmatic management."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-020-00529-8"},{"key":"e_1_3_2_5_2","first-page":"1650","article-title":"Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection","volume":"60","author":"Centers for Disease Control and Prevention (CDC)","year":"2011","unstructured":"Centers for Disease Control and Prevention (CDC). 2011. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morbidity and Mortality Wkly Report 60:1650\u20131653.","journal-title":"MMWR Morbidity and Mortality Wkly Report"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwz172"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30032-1"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy082"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2020.09.009"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.2217\/pgs-2018-0166"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.03940.x"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1806"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky378"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0222-8"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv394"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8060812"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab665"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15527"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00512-18"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0093-2"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4461"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2019.04.012"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000983"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.70"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1993.198"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2007090974"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2021.105812"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2021.07.002"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0041-3879(80)90038-0"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2021.1836158"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20180845"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv490"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104875"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2014.3158"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001098"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ323"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2018.05.013"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.11.122"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.48.113006.094708"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-006-9067-5"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01297-22","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01297-22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T14:02:43Z","timestamp":1676556163000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.01297-22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,16]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2,16]]}},"alternative-id":["10.1128\/aac.01297-22"],"URL":"https:\/\/doi.org\/10.1128\/aac.01297-22","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"type":"print","value":"0066-4804"},{"type":"electronic","value":"1098-6596"}],"subject":[],"published":{"date-parts":[[2023,2,16]]},"assertion":[{"value":"2022-09-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01297-22"}}